Is Dishman Carbogen Amcis a Good Buy After Its Q1 FY27 Results?

Dishman Carbogen Amcis share price around Rs 170. 47.1% below 52-week high of Rs 322. Q1 FY27 revenue Rs 696 crore, down 5.0% YoY. loss of Rs 58 crore.

The Dishman Carbogen Amcis share price has been under the spotlight this results season after the company reported its first-quarter numbers for FY27. Dishman Carbogen Amcis is a contract research and manufacturing (CRAMS) company serving global pharmaceutical clients, and its Q1 FY27 print, for the quarter ended June 30, 2026, gives investors a fresh data point to test whether the stock still deserves a place in a portfolio at current levels.

Revenue for the quarter came in at Rs 696 crore, down 5.0% year on year, while the company reported a net loss of Rs 58 crore. That combination of numbers is exactly what this article breaks down, along with what it means for the Dishman Carbogen Amcis share price from here.

This piece works through the quarter’s financial highlights, the business factors behind the numbers, where the Dishman Carbogen Amcis share price stands against its 52-week range and valuation multiples, and the key risks worth watching before treating this as a buy, hold or a stock to avoid for now.

Click Here – Get Free Investment Predictions

Dishman Carbogen Amcis Q1 FY27 Financial Highlights

Dishman Carbogen Amcis Q1 FY27 Performance Analysis

Check Dishman Carbogen Amcis Fundamentals on Univest Screener

Revenue declined 5.0% for the quarter, which was not offset by cost control, and the pharmaceutical contract research and manufacturing (CRAMS) business will need a stronger showing next quarter to reverse the trend.

The quarter’s most important number is the swing to a net loss of Rs 58 crore, a reversal from the profit reported a year earlier. The revenue trend does not offset this either, and the Dishman Carbogen Amcis share price should be judged on when profitability is likely to return rather than on the topline trend.

On a sequential basis, revenue moved down 19.8% sequentially from Rs 868 crore in the March 2026 quarter and the net loss moved down 366.2% sequentially from Rs 22 crore in the prior quarter, giving a fuller picture of the trend behind the Dishman Carbogen Amcis share price than the year on year comparison alone.

Key Business Factors in Q1 FY27

Revenue Trend

Dishman Carbogen Amcis’ revenue declined 5.0% year on year this quarter, taking the quarterly base to Rs 696 crore in a pharmaceutical contract research and manufacturing (CRAMS) business that remains sensitive to demand and pricing cycles that ultimately feed through to the Dishman Carbogen Amcis share price.

Margin Movement

EBITDA fell to Rs 78 crore from Rs 165 crore, and operating margin slipped to 11.3% from 23.0% a year earlier, pointing to cost or pricing pressure that management will need to manage through the rest of FY27.

Balance Sheet Position

Dishman Carbogen Amcis’ debt-to-equity ratio stands at 0.46, a level worth monitoring given the quarter’s margin trend.

Valuation Context

Dishman Carbogen Amcis does not carry a meaningful PE multiple this quarter given its current earnings, so investors should lean on revenue and book value trends instead of the price-to-earnings ratio when assessing the Dishman Carbogen Amcis share price.

Dividend Details

No interim dividend was declared alongside Dishman Carbogen Amcis’ Q1 FY27 results. The stock has not paid a meaningful dividend in the trailing twelve months. Investors tracking the Dishman Carbogen Amcis share price for income should watch the company’s announcements around its next annual results for any dividend decision.

Dishman Carbogen Amcis Share Price Outlook for FY27

Dishman Carbogen Amcis’ path back to profitability is the central question for FY27. Revenue growth is a positive signal, but until the company demonstrates it can convert that growth into profit again, the Dishman Carbogen Amcis share price is likely to stay sensitive to every quarterly update.

Investors should track cost trends and any management commentary on when profitability is expected to normalise, since that timeline will likely matter more to the Dishman Carbogen Amcis share price than revenue growth alone.

Dishman Carbogen Amcis Stock Performance

Download the Univest iOS App or Univest Android App to track Dishman Carbogen Amcis’ live share price and get daily stock updates.

The Dishman Carbogen Amcis share price was trading around Rs 170 as results season played out in late August 2026, roughly 47.1% below its 52-week high of Rs 322 and well above its 52-week low of Rs 128.

The Dishman Carbogen Amcis share price has likely already absorbed some of this quarter’s disappointment, but further downside is possible if the next results confirm the same trend rather than a one-off. On profitability ratios, the company reports a return on equity of 1.46% and a book value of around Rs 426 per share, both useful reference points when judging whether the current price is reasonable.

Key Risks

Profitability Risk

The quarter’s profit trend is the clearest risk here. Until Dishman Carbogen Amcis shows a sustained improvement in margins or the bottom line, the stock is likely to stay volatile around results.

Sector and Demand Risk

As a pharmaceutical contract research and manufacturing (CRAMS) business, Dishman Carbogen Amcis’ results remain tied to sector-specific demand, pricing and regulatory cycles that can shift from quarter to quarter and move the Dishman Carbogen Amcis share price well before the next result.

Execution Risk

Sustaining this quarter’s trend into the rest of FY27 depends on management execution on costs, pricing and demand, none of which are guaranteed.

Conclusion

Dishman Carbogen Amcis’ swing to a net loss of Rs 58 crore in Q1 FY27 is the standout number from this result, with revenue also under pressure. The Dishman Carbogen Amcis share price is best approached cautiously until the company shows a credible path back to profitability, and this quarter alone does not make a strong case to buy.

Frequently Asked Questions on Dishman Carbogen Amcis Q1 FY27 Results

What were Dishman Carbogen Amcis’ Q1 FY27 results?

Ans. Dishman Carbogen Amcis reported Q1 FY27 revenue of Rs 696 crore, down 5.0% year on year, with a net loss of Rs 58 crore.

Is Dishman Carbogen Amcis a good buy after its Q1 FY27 results?

Ans. Dishman Carbogen Amcis’ profitability came under pressure this quarter, which makes this a stock to watch rather than an obvious buy purely on this result. Investors should form their own view based on their own risk appetite and time horizon.

What is the Dishman Carbogen Amcis share price today?

Ans. The Dishman Carbogen Amcis share price was trading around Rs 170 in late August 2026, about 47.1% below its 52-week high of Rs 322 and well above its 52-week low of Rs 128.

What is Dishman Carbogen Amcis’ revenue and profit for Q1 FY27?

Ans. Dishman Carbogen Amcis reported revenue of Rs 696 crore and a net loss of Rs 58 crore for the quarter ended June 30, 2026.

Did Dishman Carbogen Amcis declare a dividend with its Q1 FY27 results?

Ans. No interim dividend was declared alongside Dishman Carbogen Amcis’ Q1 FY27 results. Investors should track the company’s next annual results for any dividend announcement.

Why does Dishman Carbogen Amcis not have a meaningful PE ratio?

Ans. Dishman Carbogen Amcis does not carry a meaningful price-to-earnings ratio currently because of its recent earnings performance. Investors should use revenue and book value trends instead when assessing the stock.

What are the key risks for Dishman Carbogen Amcis investors right now?

Ans. The quarter’s profit trend is the clearest risk here. Until Dishman Carbogen Amcis shows a sustained improvement in margins or the bottom line, the stock is likely to stay volatile around results. Sustaining this quarter’s trend into the rest of FY27 depends on management execution on costs, pricing and demand, none of which are guaranteed.

What is Dishman Carbogen Amcis’ promoter shareholding?

Ans. Promoter shareholding data for Dishman Carbogen Amcis was not fully available for this quarter and should be checked on the company’s official filings.